CLN2 gene therapy - REGENXBIO

Drug Profile

CLN2 gene therapy - REGENXBIO

Latest Information Update: 01 Mar 2016

Price : $50

At a glance

  • Originator ReGenX Biosciences
  • Developer Weill Cornell Medical College
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Neuronal ceroid lipofuscinosis

Most Recent Events

  • 01 Mar 2016 Phase-I/II development is ongoing in USA (NCT01414985)
  • 05 Sep 2013 Phase-I/II clinical trials in Neuronal ceroid lipofuscinosis in USA (Intracerebral)
  • 20 Apr 2011 Phase-I clinical trials in Neuronal ceroid lipofuscinosis in USA (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top